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ABSTRACT
Hepatitis B virus (HBV) is a major risk factor of chronic liver disease and 
hepatocellular carcinoma (HCC). Random integration of HBV DNA into the host genome is 
frequent in HCC leading to truncation of the HBV DNA, particularly at the C-terminal end 
of the HBV X protein (HBx). C-terminally truncated HBx (HBx-ΔC) has been implicated 
in playing a pro-oncogenic role in hepatocarcinogenesis. However, the mechanism 
whereby HBx-ΔC1 contributes to hepatocarcinogenesis remains unclear. In this study, 
we investigated the functional role of HBx-ΔC1 in regulating liver cancer stem cell 
(CSC) properties. Using Tet-on inducible system, we found that HBx-ΔC1 enhanced 
CSC properties including self-renewal, tumorigenicity, chemoresistance, migration and 
expression of liver CSC markers, when compared with the full-length HBx counterpart 
and vector control. Interestingly, HBx-ΔC1 conferred resistance in HCC cells towards 
sorafenib treatment through suppression of apoptotic cascade. In addition, HBx-ΔC1 
upregulated a panel of stemness genes, in which Nanog was found to be among the 
most significant one in both trasnfected cell lines. Consistently, Nanog was upregulated 
in human HCC samples which had HBx-ΔC1 expression. Furthermore, the induction of 
CSC properties by HBx-ΔC1 was via the Stat3/Nanog pathway, as administration of 
Stat3 inhibitor abolished the HBx-ΔC1-induced self-renewing capacity. In conclusion, 
our data suggest that HBx-ΔC1 enhances liver CSCs properties through Stat3/Nanog 
cascade, and provide a new insight for the therapeutic intervention for HBV-related HCC.
INTRODUCTION
Hepatocellular carcinoma (HCC) is the fifth most 
prevalent cancer and a highly lethal cancer with increasing 
worldwide incidence [1]. Chronic infection with hepatitis 
B virus (HBV) is one of the dominant etiological factors 
of HCC in Asia, accounting to 76% of all HCC cases [2]. 
HBV X protein (HBx), encoded by HBV X-gene, has been 
implicated to play a multifunctional oncogenic role in the 
development of HBV-associated HCC, such as promoting 
cell cycle progression, increasing cellular migration, 
regulating apoptotic process, inactivating negative growth 
regulators and inhibiting nucleotide excision repair of 
damaged cellular DNA [3, 4]. Accumulating evidence 
shows that random integration of HBV is detected in 
80% to 90% of the host genome from HBV-infected HCC 
cases, frequently leading to truncation of HBV genome, 
especially on the HBx gene locus at the C-terminus [5, 
6]. Our previous findings, together with other recent 
studies, have demonstrated that C-terminally truncated 
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HBx (a major C-terminal truncated form reported with a 
breakpoint at 130aa) (HBx-ΔC1) may contribute to more 
aggressive behavior of HCC, which includes enhancing 
metastasis and tumorigenicity [7–10]. However, the 
molecular mechanism underlying HBx-ΔC1 contributes to 
HCC remains largely unknown. This lack of knowledge 
presents a hurdle to the identification of novel targeted 
therapeutic strategies for this fatal disease.
Recently, increasing evidence has emerged in 
support of the existence of cancer stem cell (CSC) / 
tumor-initiating cell (T-IC) model in leukemia and a 
wide range of solid tumors, including HCC [11]. CSCs 
are believed to possess both cancer cell- and stem cell-
like characteristics, such as tumor initiation, self-renewal, 
differentiation and chemoresistance [12]. These cells 
are now regarded as the root of the tumor origin and 
recurrence. Specifically, in HCC, integrative comparative 
genomic analysis has established molecular similarities 
between CSCs and normal tissue stem cells, suggesting 
a role for liver CSCs in hepatocarcinogenesis [13]. 
Previously, we and others have demonstrated that CD24+ 
HCC cells functionally contributed to tumorigenicity and 
self-renewal though STAT3/Nanog pathway [14, 15]. 
Recently, HBx has been implicated to induce stem cell-
like and CSC-like signatures in HCC [16, 17]. In addition, 
HBx has also been shown to enhance the expansion and 
tumorigenicity of hepatic progenitor cells (HPCs) in HBx 
transgenic mice [17], suggesting the importance of HBx 
in regulating cancer stemenss. Since HBx truncation is 
frequently observed in HBV-associated HCC, it is crucial 
to examine the role of truncated HBx in regulating liver 
CSCs in HCC.
In the present study, we revealed the functional role 
of HBx-ΔC1 in regulating liver CSCs. Our data showed 
that HBx-ΔC1 induced CSC properties including self-
renewal, tumorigenicity, and drug resistance through 
the Stat3/Nanog cascade. Taken together, the current 
findings provide a better understanding on the molecular 
mechanism of HCC development associated with 
chronic HBV infection, and will significantly improve 
our knowledge of HCC pathogenesis with the goal of 
developing a more effective management for this deadly 
disease.
RESULTS
HBx-ΔC1 expressing cells increased the 
expression of stemness-related genes
Using lentiviral based Tet-On overexpression 
approach, we have successfully established inducible 
expression of HBx-FL and HBx-ΔC1 [8] in Bel-7402 and 
SMMC-7721 cells upon the addition of doxycycline at 
1 μg/ml (Figure 1A). To determine the optimal time of 
gene induction, we examined the effect of HBx-FL and 
HBx-ΔC1 on the induction of stemness-related genes 
ranging from Day 5 to Day 27 and Day 6 to Day 9 in 
Bel-7402 and SMMC-7721 transfectants, respectively 
(Supplementary Figure 1). We found a stepwise increase 
in expression of stemness-related genes including Nanog 
and Sox2 from Empty vector (EV), HBx-FL to HBx-ΔC1 
transfectants derived from Bel-7402 from Day 23 onwards 
(Figure 1B and Supplementary Figure 1). Similar effect 
on expression of stemness-related genes was observed 
in HBx-ΔC1 expressing SMMC-7721 transfectants with 
shorter doxycycline incubation time from day 6 onwards. 
(Figure 1B). To further verify this finding, we examined 
the expression of Nanog and Sox2 in transfectants of EV, 
HBx-FL, and HBx-ΔC1 in Bel-7402 and SMMC-7721 
by western blot analysis (Figure 1C). However, only 
Nanog was found to be markedly increased in HBx-ΔC1 
expressing Bel-7402 and SMMC-7721, when compared 
with EV and HBX-FL. Based on these data, it suggests the 
possible link between HBx-ΔC1 and Nanog.
HBx-ΔC1 expressing cells were endowed with 
enhanced tumorigenicity, self-renewal, and 
expression of CSC markers
CSCs are believed to possess the stem/progenitor 
properties of expression of CSC markers [18], self-
renewal [19], and tumorigenicity in immunodeficient mice 
[20]. Based on the results observed in Figure 1B and 1C, 
all functional CSC assays were performed based from Day 
23 and Day 6 onwards upon doxycycline administration 
in Bel-7402 and SMMC-7721 cells, respectively. First, 
we found that overexpression of HBx-ΔC1 increased 
the expression of liver CSC markers including CD133 
and CD47 when compared with control and HBx-FL 
expression in Bel-7402 and SMMC-7721 (Figure 2A). 
Accompanied with these changes, we found that HBx-
ΔC1 transfectants exhibited increased self-renewal ability, 
as evidenced by the increase in the number and size of 
the spheres and their passages in sphere formation assay 
(Figure 2B). Next, we examined whether C-terminal 
truncated form of HBx was more tumorigenic than full-
length HBx in vivo by tumor forming assay with HBx-
FL expressing and HBx-ΔC1 expressing Bel-7402 and 
SMMC-7221 cells. Cells at density of 5000, 10000 and 
50000 were inoculated subcutaneously into NOD/SCID 
mice. An increase in tumor incidence and size was 
observed in HBx-ΔC1 expressing cells when compared 
with control and HBx-FL expressing cells (Figure 2C).
HBx-ΔC1 conferred chemoresistance and 
migratory properties to HCC cells
Our previous studies have demonstrated that liver 
CSCs are more chemoresistant to chemotherapeutic drugs 
[21, 22]. Thus, we assessed whether HBx-ΔC1 conferred 
chemoresistance to HCC cells. For this purpose, we 
treated the transfectants of EV, HBx-FL and HBx-ΔC1 
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derived from Bel-7402 and SMMC-7721 with cisplatin 
and doxorubicin and subjected them to Annexin V 
staining assay. HBx-ΔC1 transfectants was found to be 
more chemoresistant to cisplatin and doxorubicin when 
compared with EV and HBx-FL transfectants in both Bel-
7402 and SMMC-7721 cells (Figure 3A). In our previous 
study, we found that HBx-ΔC1 was significantly correlated 
with more aggressive phenotype of HCC patients [8]. 
Consistent with that clinical observation, we found that 
overexpression of HBx-ΔC1 conferred greater migratory 
ability to HCC cells, when compared with control and 
HBx-FL overexpression (Figure 3B).
HBx-ΔC1 preferentially conferred resistance 
to sorafenib through suppression of 
apoptotic pathway
Previously, we found that liver CSCs were enriched 
upon sorafenib treatment, as evidenced by an increase 
in the abilities in self-renewal and tumorigenicity in 
Figure 1: HBx-ΔC1 expressing cells increased expression of stemness-related genes. A. Direct protein lysates of control 
and HBx expressing Bel-7402 and SMMC-7721 cells were collected after adding doxycycline for 23 and 6 days respectively and 
confirmed that HBx-FL and HBx-ΔC1 proteins were successfully expressed in respective transfected Bel-7402 and SMMC cells, by 
indirect immunoblotting using c-myc antibodies to detect myc-tagged-Hbx-FL and HBx-ΔC1 protein. B. qPCR analysis revealed HBx-ΔC1 
expressing Bel-7402 had increased expression of stemness-related genes including of Nanog and Sox2 after adding doxycyclines for 23 
days when compared with control (EV) and HBx-FL expressing Bel-7402. After adding doxycycline for 6 days, HBx-ΔC1 expressing 
SMMC-7721 cells had increased mRNA expression of Nanog and Sox2 when compared with EV and HBx-FL expressing SMMC-7721. 
C. Western blot analysis showed that Nanog was found to be preferentially expressed in transfectants of HBx-ΔC1, when compared with 
those with EV and HBx-FL.
Oncotarget23510www.impactjournals.com/oncotarget
sorafenib-resistant cells [22]. Since HBx-ΔC1 upregulated 
the traits of liver CSCs as shown in Figures 2 and 3, 
we hypothesized that HBx-ΔC1 conferred resistance 
to sorafenib treatment. For this purpose, we compared 
the sensitivity towards sorafenib among HBx-FL and 
HBx-ΔC1 transfectants of Bel-7402 and SMMC-7721 
and their controls. By Annexin V staining, HBx-ΔC1 
transfectants was found to be more resistant to sorafenib 
when compared with EV and HBx-FL transfectants in both 
Bel-7402 and SMMC-7721 cells (Figure 4A). To further 
understand the underlying molecular mechanism for 
sorafenib resistance conferred by HBx-ΔC1, we examined 
the expression of apoptosis cascade proteins including 
Bax, Bcl2, and cleaved forms of PARP, caspase-3 and 9 
in the transfectants of EV, HBx-FL and HBx-ΔC1 derived 
from Bel-7402 and SMMC-7721 in response to sorafenib 
treatment. As shown in Figure 4B, HBx-ΔC1 transfectants 
demonstrated decreased Bax/Bcl2 ratio and expression of 
cleaved forms of PARP, capcase-3 and -9, when compared 
with EV and HBx-FL transfectants in both Bel-7402 and 
SMMC-7721 cells.
HBx-ΔC1 driven tumor initiation and self-
renewal through Stat3/Nanog signaling
Previously, we found that Stat3/Nanog pathway was 
activated in liver CSCs contributing to tumorigenicity 
and stemness [15]. In addition, Stat3 signaling activity 
has been shown to be enhanced in HBx expressing cells 
and HBx transgenic mice leading to carcinogenesis [17]. 
Therefore, we investigated if Stat3-mediated Nanog 
regulation was involved in the enhancement of cancer 
stemness by truncated HBx. By western blotting, we found 
that HBx-ΔC1 preferentially induced the expression of 
Stat3 (Y705) and stem cell transcriptional factor, Nanog, 
in Bel-7402 and SMMC-7721 (Figure 5A). We also 
determined the Stat3 activity by quantifying the phospho-
Stat3 (p-Stat3 [Y705]) level using immunofluorescence 
staining. Consistently, HBx-ΔC1 stimulated Stat-3 
activity as indicated by higher percentage of p-Stat3 
(Y705) staining when compared with control and HBx-FL 
(Figure 5B). We also examined the expression of a panel 
of stemness genes in the HCC clinical samples by qPCR 
Figure 2: HBx-ΔC1 expressing cells possessed enhanced CSC properties. A. Flow cytometry analysis revealed increased 
expression of CSC markers including CD47 and CD133 in HBx-ΔC1 clones when compared with control (EV) and HBx-FL clones in 
both Bel-7402 and SMMC-7721 (*p<0.05, **p<0.01, Student’s t test). B. Spheroid formation after 8-10 days (10X objective) showed that 
both HBx-ΔC1 expressing Bel-7402 and SMMC-7721 cells had increased number and size of hepatospheres formed when compared with 
respective control (EV) and HBx-FL expressing cells (*p<0.05, **p<0.01, ***p<0.001, Student’s t test). P1 and P2 = passage 1 and 2, 
respectively C. Control, HBx-FL- or HBx-ΔC1 expressing Bel-7402 and SMMC-7721 cells were injected subcutaneously at 4 sites (2 in the 
right flank and 2 in the left flank) per NOD/SCID mouse in three different cell numbers (5000, 10000, 50000 cells). HBx-ΔC1 expressing 
cells exhibited increased tumor-forming incidence and size when compared with EV and HBx-FL expressing cells. For SMMC-7721, no 
tumor was formed in all three clones when 5000 cells were injected (data not shown).
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Figure 3: HBx-ΔC1 conferred resistance to chemotherapeutic drugs and enhanced cell migration. A. HBx-ΔC1 
overexpression conferred resistance to chemotherapeutic drugs including cisplatin and doxorubicin in both Bel-7402 and SMMC-7721, 
when compared to respective EV and HBx-FL, (Cisplatin: Bel-7402: 47.5% vs 82.1% and 62.5%; SMMC-7721: 33.5% vs 40.9% and 
45.6%); and (Doxorubicin: Bel-7402: 48.3% vs 61.1% and 66.9%; SMMC-7721: 36.1% vs 45.2% and 53.2%) after treatment for 48hr 
at 0.25 and 2 μg/ml at 2% serum containing medium, 48hr at 4 and 10 μg/ml at 2% serum containing medium, respectively (*p<0.05, 
**p<0.01, ***p<0.001, Student’s t test). B. Light micrograph of the cell migration assays, with staining of the cells in the lower chamber 
(4× objective), demonstrated that HBx-ΔC1 overexpression was more potent to enhance metastatic ability of cells in both Bel-7402 and 
SMMC-7721 clones (*p<0.05, **p<0.01, ***p<0.001, Student’s t test).
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(Supplementary Figure 2). Consistently, Nanog expression 
was found to be up-regulated in the tumor samples with 
detectable expression of HBx-ΔC1 when compared to 
those with full-length HBx or without HBV infection 
(Figure 5C). To further examine whether the HBx-induced 
upregulation of Nanog was Stat3-dependent, we examined 
the p-Stat3 (Y705) and Nanog expression in the presence 
of a Stat3 inhibitor (S3I-201) in Bel-7402 and SMMC-
7721 cells. By western blot analysis, Nanog expression 
was found to be downregulated upon S3I-201 treatment 
(Figure 6A). Furthermore, addition of S3I-201 abolished 
the HBx-induced self-renewal as indicated by sphere 
forming assay (Figure 6B). Taken together, these findings 
suggest that HBx-ΔC1 enhances liver CSCs properties 
through Stat3-mediated Nanog upregulation.
DISCUSSION
HBV DNA is often integrated and highly rearranged 
within the host DNA in HCC [23]. Among the four 
Figure 4: HBx-ΔC1 enhanced the resistance to sorafenib-induced apoptosis. A. HBx-ΔC1 overexpression enhanced sorafenib 
resistance in both Bel-7402 and SMMC-7721, when compared to EV and HBx-FL expressing cells (Bel-7402: 47.4% vs 65.8% and 
55.8%; SMMC-7721: 29.8% vs 35.2% and 37.0%), after treatment for 48hr at 10 and 20 μM at 5% serum containing medium respectively 
(*p<0.05, **p<0.01, ***p<0.001, Student’s t test). B. HBx-ΔC1 overexpression reduced apoptotic signaling pathway by decreasing the 
Bax/Bcl2 ratio, indicator of apoptosis, the expression of activated cleaved form of caspase 9 and 3 and PARP when compared to control 
and HBx-FL expressing cells.
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proteins translated by HBV, the X-gene product (HBx), 
active in transactivation assay [24], has been closely 
associated with the HCC carcinogenesis. In the present 
study, we demonstrated that the expression of HBx-ΔC1 
contributed to cancer stemness and tumorigenicity of 
HCC, providing novel evidence for the role of HBx-ΔC1 
in HBV-infected liver cancer.
Recently, hepatitis B virus-infected hepatocytes 
induced a CSC-like gene signature with EpCAM 
upregulation [25]. In addition, HBx enhanced expression 
of stemness and CSC markers including Oct4, Nanog, 
Klf-4, and EpCAM in vitro and enhanced the expansion 
and tumorigenicity of hepatic progenitor cells (HPCs) 
in HBx transgenic mice [16, 17]. Consistent with the 
previous findings, we found that HBx enhanced the 
expression of stemness genes including Nanog and Sox2. 
Since COOH-truncated form of HBx has been shown 
to have more aggressive behavior in the development 
of HCC [7–10], in this study, in addition to full-length 
HBx, we also studied the role of COOH-truncated 
HBx, with a breakpoint at 130aa (HBx-ΔC1) [5, 6, 8, 
26] in the regulation of cancer stemness. Interestingly, 
we demonstrated that HBx-ΔC1 enhanced the liver 
CSC properties including increased expression of 
stemness genes, self-renewal capacity, resistance to 
chemotherapeutic drugs and tumorigenesis, all these 
effects being more prominent than the full-length HBx. 
These results have demonstrated the distinct role of HBx-
ΔC1 in promoting liver CSC properties.
Sorafenib is the only FDA-approved molecularly 
targeted drug shown to improve the survival of 
unresectable HCC. However, the survival benefit of 
the sorafenib treatment arm was on average only 2-3 
months longer [27], partly due to drug resistance. 
In order to understand the molecular mechanism of 
sorafenib resistance, we previously established sorafenib-
resistant HCC cells which were found to exhibit liver 
CSC properties including enhanced self-renewal 
Figure 5: HBx-ΔC1 regulated liver CSC properties through Stat3-Nanog signaling. A. Western blot analysis revealed 
that HBx-ΔC1 expressing Bel-7402 and SMMC-7721 cells had increased Stat3 phosphorylation (Y705) and expression of Nanog, when 
compared to respective EV and HBx-FL expressing cells. B. Increased fluorescent nuclear staining of p-Stat3 (Y705) was observed in HBx-
ΔC1 cells in both Bel-7402 and SMMC-7721when compared with respective EV and HBx-FL, as analyzed by immunefluorescence (IF) 
staining (40X objective). Stained cells were classified into 4 groups as per the fluorescent intensity measured by Photoshop CS5. C. qPCR 
analysis demonstrated that the expression of Nanog was up-regulated in HCC samples detected with HBx-ΔC1 (n=48) when compared with 
those with HBx-negative and HBx-FL (n=59) (*p=0.03, t test).
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capacity and tumorigenicity, when compared with their 
mock counterparts [22]. Since HBx-ΔC1 was found to 
upregulate liver CSC properties, we examined whether 
it conferred resistance to sorafenib treatment though 
enhancement of liver CSC properties. We found that 
HBx-ΔC1 suppressed the apoptotic cascade and thereby 
decreased the sensitivity of HCC cells towards sorafenib 
treatment. In this regard, HBx-ΔC1 may be a potential 
predictor for sorafenib response.
Stat3 activation has been found to be important 
in the maintenance of survival of liver CSCs (14). We 
and others have previously demonstrated that Nanog is 
the direct downstream effector of Stat3 in the regulation 
of tumorigenicity and self-renewal of liver CSCs and 
glioblastoma stem cells [15, 28]. Nanog is a self-renewal 
gene that maintains the pluripotency of embryonic stem 
cells [29]. Recently, it has been identified as a novel 
oncogene by a large-scale oncogenomics analysis 
[30], and it is also crucial in regulating human tumor 
development [31]. In addition, Stat3 signaling activity 
has been demonstrated to be enhanced in HBx expressing 
cells and HBx transgenic mice leading to carcinogenesis 
[17, 32]. Consistently, we found the upregulation of 
nuclear Stat3, p-Stat3 and Nanog expression in HBx-
expression cells (Figure 4A and 4B). We found the Stat3/
Nanog signaling pathway was preferentially activated 
in HBx-ΔC1 trasnfectants, which was indicated by the 
enhanced activity of Stat3 and expression of Nanog 
observed in HBx-ΔC1 expressing Bel-7402 and SMMC-
7221 cells, when compared with HBx-FL and control 
cells. Furthermore, the role of HBx-ΔC1-induced self-
renewal was confirmed by the treatment with Stat3 
inhibitor. We found that the inhibition of Stat3 activation 
using a Stat3 specific inhibitor abrogated the effect of the 
HBx-ΔC1-induced self-renewal capacity. These findings 
suggest that Stat3-Nanog signaling plays a crucial 
role in regulating the stemness properties mediated by 
HBx-ΔC1.
In summary, the present findings demonstrated 
that HBx-ΔC1 plays a critical role in HCC development 
and progression via the regulation of cancer stemness, 
which involves the preferential activation of the Stat3-
Nanog pathway. A better understanding of the molecular 
mechanism of HBx-ΔC1 will improve our knowledge of 
HCC pathogenesis with the goal of developing a more 
effective management for this deadly disease. Our data 
also give a new insight on developing targeted therapies 
against HBx-ΔC1-induced Nanog and the identification 
of novel markers to predict disease outcome and tumor 
recurrence.
Figure 6: Effect of Stat3 inhibitor on HBx-induced self-renewal. A. Nanog expression was found to be down-regulated upon 
treatment with S3I-201 for 24hr, as analyzed by western blot analysis. B. Pre-treatment of S3I-201 at the concentration of 100 and 150μM 
led to abolishment of HBx-ΔC1-induced self-renewal indicated by sphere forming assay where the number and size of sphere formed (4X 




Full-length HBx DNA (GenBank no.: U95551) was 
amplified from the HBx/pcDNA3.1+ plasmid [8] and sub-
cloned into Myc/pLVX-Tight Puro and Myc/pcDNA3.1+ 
vectors. HBx truncation mutant (named HBx-ΔC1) with 
24 C-terminal amino acid of HBx deleted was made 
and sub-cloned into Myc/pLVX-Tight Puro and Myc/
pcDNA3.1+ vectors.
Cell lines
The human HCC cell lines Bel-7402 and SMMC-
7721 (SIBS, Chinese Academy of Sciences) were grown in 
Dubecco's modified Eagle minimal high glucose essential 
medium (DMEM-HG) (Gibco-BRL) supplemented with 
10% fetal bovine serum (FBS) (Gibco-BRL) and 1% 
penicillin and streptomycin (Gibco-BRL).
Human HCC samples
107 human HCCs liver tissues from patients with 
liver resection for HCC between 1992 and 2010 at Queen 
Mary Hospital, Hong Kong, were randomly selected 
for study, in which, 102 patients had positive serum 
hepatitis B surface antigen (HBsAg) status. Patients' 
ages ranged from 27 to 74 years; 68 were male and 39 
female. All specimens collected were either snap-frozen 
in liquid nitrogen and stored at -80°C, or fixed in 10% 
formalin for paraffin embedding. Use of human specimens 
was approved by the institutional review board of the 
University of Hong Kong/Hospital Authority Hong Kong 
West Cluster.
Establishment of tetracycline-inducible HBx 
expressing cells
The Bel-7402 and SMMC-7721 cell line was, 
first, transfected with pLVX Tet-On Advanced vector 
(Clontech Laboratories, Inc., Mountain View, CA) 
using Lipofectamine 2000 (Invitrogen), according to 
manufacturer's protocol. tTA (Tet-On) expressing Bel-
7402 and SMMC-7721 cells were selected with G418 at 
700 μg/mL and 400 μg/mL for 14 days, respectively. To 
obtain stable inducible HBx expressing cells, lentivirus 
containing full-length and C-terminal truncated HBx 
in Myc/pLVX-Tight Puro vector was infected into tTA 
expressing Bel-7402 and SMMC-7721 cells and selected 
with puromycin at 1 μg/mL for 7 days.
Statistical analysis
All statistical analyses were performed using the 
statistical software SPSS 17 for Windows (SPSS Inc., 
Chicago, IL). Student’s t was used for continuous data 
wherever appropriate. p values less than 0.05 were 
considered significant.
Additional experimental procedures are provided in 
the Supporting Information.
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